Atossa Genetics, Inc. Regains Compliance With NASDAQ Listing Requirement
(firmenpresse) - SEATTLE, WA -- (Marketwired) -- 09/13/16 -- (NASDAQ: ATOS) today announced it has received notice from NASDAQ that Atossa has regained compliance with NASDAQ minimum closing bid price listing rule 5550(a)(2). On September 12, 2016, Atossa received notice from NASDAQ stating, in part, that the "Staff has determined that for the last 10 consecutive business days, from August 26 to September 9, 2016, the closing bid price of the Company''s common stock has been at $1.00 per share or greater. Accordingly, the Company has regained compliance with Listing Rule 5550(a)(2) and this matter is now closed."
Atossa Genetics, Inc. is a clinical-stage pharmaceutical company developing novel therapeutics and delivery methods to treat breast cancer and other breast conditions. For more information, please visit .
Forward-looking statements in this press release, which Atossa undertakes no obligation to update, are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions and inactions by the FDA, the outcome or timing of regulatory approvals needed by Atossa, lower than anticipated rate of patient enrollment, results of clinical studies and timing of publication of those results, the safety and efficacy of Atossa''s products and services, performance of clinical research organizations and investigators, obstacles resulting from proprietary rights held by others including with respect to Fulvestrant, such as patent rights, and other risks detailed from time to time in Atossa''s filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 13.09.2016 - 06:00 Uhr
Sprache: Deutsch
News-ID 1457717
Anzahl Zeichen: 3301
contact information:
Contact person:
Town:
SEATTLE, WA
Phone:
Kategorie:
Biotech
Typ of Press Release:
type of sending:
Date of sending:
Anmerkungen:
Diese Pressemitteilung wurde bisher 118 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Atossa Genetics, Inc. Regains Compliance With NASDAQ Listing Requirement
"
steht unter der journalistisch-redaktionellen Verantwortung von
Atossa Genetics, Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
